Immuneering Q1 FY26 net loss narrows to $13.5 million

Immuneering Corp. Class A

Immuneering Corp. Class A

IMRX

0.00
  • Immuneering posted a net loss attributable to common stockholders of USD 13.5 million, or USD 0.21 per share, for Q1 2026, narrowing from a loss of USD 15 million, or USD 0.42 per share, a year earlier.
  • R&D expense slipped 7.2% to USD 10.6 million, while G&A costs rose 16.8% to USD 4.7 million.
  • Cash, cash equivalents and marketable securities totaled USD 198.6 million at March 31, down from USD 217 million at Dec. 31, with runway expected into 2029.
  • Phase 3 MAPKeeper 301 trial of atebimetinib with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer is recruiting, with first patient dosing on track for mid-2026.
  • New survival data from 55 first-line pancreatic cancer patients in a Phase 2a atebimetinib combination cohort are set for an oral presentation at the 2026 ASCO Annual Meeting on June 1.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.